BPC-157: what the evidence actually says about the 'healing peptide'
BPC-157 — short for "Body Protection Compound 157" — is a 15-amino-acid peptide derived from a protective sequence found in human gastric juice. In the peptide world, it has a near-mythical reputation: forums attribute everything from torn rotator cuffs to leaky gut to chronic tendinitis. The reality is more nuanced.
What the literature actually shows
The bulk of BPC-157 research is preclinical — primarily in rats and other animal models. Across that literature, BPC-157 has demonstrated:
- Accelerated healing of transected Achilles tendons (Chang 2011)
- Protective effects on the gastric mucosa across models of NSAID and stress-induced ulceration (Sikiric 2011)
- Protective effects on damaged ligaments, muscle, and bone in animal models
- Effects on neurological and cardiovascular tissue in animal models
The published human clinical literature is much smaller. Most clinical use of BPC-157 today is informed by clinician experience, off-label prescribing under supervision, and extrapolation from the preclinical work — not large RCTs.
This isn't unique to BPC-157. Many compounded peptides (sermorelin, thymosin alpha-1, TB-500) sit in a similar place: strong preclinical evidence, smaller clinical evidence, prescribed off-label.
How BPC-157 is typically prescribed
Compounded BPC-157 is most often prescribed for:
- Soft-tissue injuries that haven't responded to conservative care (tendinopathy, ligament strains)
- Post-surgical recovery support
- GI inflammation and ulceration (oral form)
Subcutaneous injection 1–2x daily for a 4–8 week cycle is the most common protocol. Doses are individualized — your clinician will not give you a one-size-fits-all script.
What "research-grade" BPC-157 is, and why we don't sell it
If you've searched for BPC-157 online, you've seen vendors selling vials labeled "for research use only — not for human consumption." This labeling is a workaround. The product is sourced from chemical suppliers with no FDA registration, no third-party assays, no sterility testing, and no clinical oversight.
Peptide12 does not source from research-chemical suppliers. We work with FDA-registered 503A and 503B compounding pharmacies that test every batch for identity, potency, sterility, and endotoxin. That's the line.
Who shouldn't use BPC-157
- Active malignancy or recent cancer history (BPC-157's angiogenic effects warrant caution)
- Pregnancy or active attempts to conceive
- Anyone without a clear clinical indication
The bottom line
BPC-157 has a real preclinical signal for soft-tissue healing and a smaller-but-growing clinical track record. It's not a miracle peptide and it's not snake oil — it's a tool with a specific use case, prescribed under clinician supervision, sourced from regulated US pharmacies.
If you're considering it, the right starting point is a clinical review with someone who can look at your specific injury, history, and goals — not a forum post.